Get the Stockscreener App
33.05
4.65%
1.47
Olema Pharmaceuticals Inc stock is traded at $33.05, with a volume of 3.28M.
It is up +4.65% in the last 24 hours and up +310.05% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$31.58
Open:
$32.14
24h Volume:
3.28M
Relative Volume:
0.95
Market Cap:
$2.65B
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-15.37
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
+21.46%
1M Performance:
+310.05%
6M Performance:
+714.04%
1Y Performance:
+391.82%
1-Day Range:
$31.32
$33.44
1-Week Range:
$25.62
$33.50
52-Week Range:
$2.86
$33.50
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
33.05 | 2.53B | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Birchview Capital LP Invests $571,000 in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Raised to $48.00 - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Raised to $60.00 - MarketBeat
OLMA Stock: Citigroup Raises Price Target to $60, Maintains Buy - GuruFocus
Olema Pharmaceuticals (OLMA): HC Wainwright & Co. Raises Price T - GuruFocus
Olema Oncology (OLMA) Price Target Raised by Citi Amid Positive Trial Data - GuruFocus
Oppenheimer Raises Price Target for Olema Pharmaceuticals (OLMA) to $48 | OLMA Stock News - GuruFocus
OLMA: Goldman Sachs Raises Price Target to $38 on Maintained Buy Rating | OLMA Stock News - GuruFocus
The Goldman Sachs Group Issues Positive Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 6% Following Analyst Upgrade - MarketBeat
Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT - Finviz
HC Wainwright Raises Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $45.00 - MarketBeat
Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright - Investing.com Canada
HighVista Strategies LLC Acquires 66,245 Shares of Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Jefferies raises Olema Pharmaceuticals stock price target to $43 on SERD validation - Investing.com UK
Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know - ts2.tech
Olema Pharmaceuticals (NASDAQ:OLMA) Hits New 1-Year HighHere's Why - MarketBeat
Olema Oncology (OLMA) Shares Surge Over 11% - GuruFocus
Olema Pharmaceuticals stock hits 52-week high at $29.57 By Investing.com - Investing.com Canada
Roche's SERD Trial Boosts Olema Pharmaceuticals (OLMA) Stock - GuruFocus
Olema Pharmaceuticals stock hits 52-week high at $29.57 - Investing.com
Diadema Partners LP Increases Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Sets New Standards In Oncology - Kalkine Media
Olema Pharmaceuticals joins SABCS25 to advance breast cancer therapies - Traders Union
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 7.7%Here's Why - MarketBeat
Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025 - ts2.tech
Olema Pharmaceuticals (NASDAQ:OLMA) Moves Forward with Clinical Trials - Kalkine Media
XTX Topco Ltd Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals, Inc. $OLMA Shares Bought by Schroder Investment Management Group - MarketBeat
Affinity Asset Advisors LLC Lowers Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals (OLMA) price target increased by 53.92% to 37.23 - MSN
Olema Pharmaceuticals Inc Stock Analysis and ForecastVolume Profile Analysis & Turn Data into Profits With Our Strategies - earlytimes.in
Why Olema Pharmaceuticals Inc. stock is rated strong buyChart Signals & Capital Protection Trade Alerts - Newser
Why retail investors favor Olema Pharmaceuticals Inc. stockMarket Sentiment Review & Long-Term Growth Plans - Newser
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals seeks senior medical director to advance oncology care - Traders Union
Olema Pharmaceuticals (OLMA) Stock Analysis Report | Financials & Insights - Benzinga
H.C. Wainwright Backs Olema Pharmaceuticals (OLMA) as Phase 3 Trials Advance - MSN
Olema Pharmaceuticals (OLMA): Assessing Valuation Following $190 Million Equity Offering and Underwriter Changes - Sahm
Olema Pharmaceuticals (NASDAQ:OLMA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Will Olema Pharmaceuticals Inc. stock pay special dividends2025 Price Targets & Weekly Watchlist for Hot Stocks - BỘ NỘI VỤ
Olema Pharmaceuticals stock hits 52-week high at 27.25 USD By Investing.com - Investing.com Canada
Olema Pharmaceuticals stock hits 52-week high at 27.25 USD - Investing.com
15,000 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by Titleist Asset Management LLC - MarketBeat
Olema Pharmaceuticals : Statement of Changes in Beneficial Ownership (Form 4) - marketscreener.com
Dir Rappaport Acquires 35,868 Of Olema Pharmaceuticals Inc [OLMA] - TradingView
[Form 4] Olema Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Olema Pharmaceuticals Reports Increased Losses Amid R&D Expansion - MSN
Olema Pharmaceuticals (OLMA): Evaluating the Current Valuation After a Strong Run-Up in Recent Months - Yahoo Finance
Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA) - MSN
LifeSci Capital Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA) - The Globe and Mail
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):